鹅细小病毒病是由鹅细小病毒引起雏鹅的急性、亚急性和败血性传染病，呈世界性分布。该病的发病率和死亡率均较高，临床一旦发病，无有效治疗办法，严重危害养鹅业的健康发展。因此，迫切需要有效的疫苗防制该病的发生。传统疫苗存在毒力返强、灭活不彻底等潜在危险，基因工程疫苗弥补了这些不足。大量研究提示，禽痘病毒活载体疫苗能持续表达外源保护性抗原基因，诱导禽类产生长期的体液免疫和细胞免疫，而IFNγ具有免疫调节作用，可减轻活病毒载体给机体带来的毒副作用。目前，关于鹅IFNγ基因与鹅细小病毒保护性抗原基因联合重组禽痘病毒疫苗的相关研究尚属空白。本研究拟以能刺激机体产生中和抗体的鹅细小病毒VP3基因为保护性抗原基因，鹅IFNγ基因为调节基因，构建两种基因的单表达与共表达重组禽痘病毒疫苗，通过免疫试验和攻毒试验，评价各组疫苗的免疫保护作用并阐明免疫机制。本研究将为鹅细小病毒病的新型疫苗研制提供理论依据。

Goose Parvovirusis(GP) is an acute and sub-acute septicemic infectious disease caused by goose parvovirus (GPV)and is prevalent worldwide. This disease can cause serious problem for the development of goose industry because of its high incidence and mortility and there are still not effective therapeutic measurements. Therefore, it is imperative to develop effective vaccine. Virulence reversion and incomplete inactivation are the disadvantages of the traditional vaccine gene engineering vaccine could solve these problems.Previous studies indicated live fowlpox virus vectored vaccines could express foreign protective gene constantly and stimulate long term humoral and cellular immunity. At the same time, it was reported interferon gamma could be used as an adjuvant to reduce the side effect of virus vectored vaccines. Currently, fowlpox virus expressing both protective antigens of goose parvovirus and goose interferon gamma has not yet been evaluated. In this study, the goose parvovirus VP3 gene, which could stimulate neutralizing antibodies and goose interferon gamma gene will be used to construct recombinant fowlpox virus. The protectivity of the recombinant virus vaccine expressing both factors or individual gene will be evaluated and the related mechanism will be investigated.The study will lay the foundation for the control and novel vaccine development of goose parvovirusis.